

Breakthrough in Cancer Treatment

ViDAC Pharma is a pre-IPO clinical stage biopharmaceutical company developing first-in-class anti-cancer drugs by modifying the hyper glycolytic (Warburg Effect) Tumor Micro Environment.

ViDAC's innovations target cancer cells overexpressed Hexokinase 2 metabolic checkpoint (HK2) to **selectively kill cancer cells without affecting surrounding normal tissue**. ViDAC's drugs intervene in the cancer cells' nutrition, triggering dormant self-death mechanism (i.e., the apoptosis) returning cells to normal metabolism **thus reducing immune depression** in tumor's environment while stimulating **anti-tumor immune response** in selected cancer cells only.

Lead first drug: topical *tuvatexib* (VDA-1102) presents highest safety and selective efficacy in patients with **Actinic Keratosis (AK/topical SCC)** as demonstrated in a FDA Phase 2b clinical trial (2019) and in on-going exploratory Phase 2 in **Cutaneous T Cell Lymphoma (CTCL)**.


We are at advanced pre-clinical stage and developing new patented very potent new molecules with the same MOA for addressing solid tumors either as single treatment or in combination with immunotherapy and cell therapy which effect is impaired by hyper glycolysis of the Tumor microenvironment.

Market

CTCL represents an unmet medical need of \$900M worldwide equally divided between USA, Europe and Asia Pacific area. It is classified by FDA as Rare disease commending a fast track regulatory pathway. Global trends such as aging population, global warming and sun exposure in developed and emerging countries **contributes** to further grow ViDAC Pharma's total available market in the coming years.

Today, over 200 million **Non-Melanoma Skin Cancer (NMSC)** patients worldwide face inadequate treatment options to treat their debilitating recurring and even life-threatening diseases. Market opportunity includes more than \$500 Million annual sales for first indication and more than \$2 Billion annual sales across all indications for non-surgical removal of the tumors.

The Solid Tumor market is a multibillion \$ market lacking products for critical cancer such as Pancreas, Prostate, Lung etc. which are all hyper glycolytic cancers





Lead Products: VDA-1102 for Non-Melanoma Skin Cancer and CTCL

ViDAC's pipeline includes several first-in-class **potential** drug candidates for a variety of indications.

VDA-1102 is a very potent, highly selective anti-cancer drug applied topically on skin to treat Actinic Keratosis (AK) recurring disease with incidence rate increasing with age as a primary indication. VDA-1102's mechanism of action, high efficacy and specificity towards cancer cells, position it as a high potential anti-cancer product for large range of NMSC such as CTCL, Squamous Cell Carcinoma (SCC) and Basal Cell Carcinoma (BCC). Unlike existing drugs generating severe side effects and pain, VDA-1102 is a first-in-class drug that treats NMSC without adversely affecting the surrounding healthy skin. Because of its unique characteristics and benefits, VDA-1102 is to become the drug of choice for first-line non-surgical treatment in a wide range of NMSC indications.

Recent data showing **the potential of the drug for the treatment of CTCL** and the fact that the Phase 1 and 2 made on AK showed exceptionally rare adverse effect, is the regulatory basis for going directly into a Phase 2 which begun (Dec 2020) on this extremely painful disease which lacks adequate medical treatment. Because of its classification, Exploratory Phase 2 comprises 20-30 patients looking for dose and protocol finding and about the same number of a qualified FDA Phase 2 and it is expected that phase 3 will demand as few as 100-150 patients. Exploratory CTCL Phase 2a is on-going in Israel and a Phase 2A planed in USA and Europe under the supervision of Prof. Emilia Hodak from Beilinson Hospital in Israel and one of the KOL on this disease.

Business Opportunity

Following **further** in-depth analysis of VDA-1102 Phase 2 results (2019) in Actinic Keratosis (Topical SCC), the management team discovered an unmatched success rate treatment for a selective population. The team decided to conduct an additional re-formulated complementary Phase 2b focused on a slight protocol modification to test this population in parallel with the present formulation allowing targeted claims for Phase 3 (2022). It is expected that this slight modification might give a dramatic enhancement of the drug power which will govern the nature of the Phase 3. This de-risked clinical trial will have updated endpoints while repeating the results previously obtained in Phase 2

While the post Corona COVID19 might delay for a while completion of this phase 2c and 3 for AK due to the present reluctance of aged population to participate in clinical trials for a skin disease, it offered a rare opportunity to begin a Phase 2 for CTCL (on-going) which is a more critical disease, for which patients are ready to try alternative treatments which might relieve them from the pain, look and itching accompanying CTCL.

Contact Information:

Max Herzberg PhD, direct +972544257381 or maxherzberg@gmail.com



The new Management by seasoned entrepreneur industrials and a new team of highly experienced executive managers conduct further developments. The business opportunity resides in joining a top recognized team of experts who bought-out their company to develop promising anti-cancer treatment based on previously accomplished research and development (\$19M invested in previous cycle including \$5M from Innovation Authorities in Israel). The Company intends to become Public in a major European Stock Exchange Q1-Q2 2022.

Financing Plan

Stage 1: We are looking for a Mezzanine investment before Registering the Company in Europe Stock exchange during 2022. Funding will be used to achieve a 20-30 patients Phase 2 in CTCL (Q2 2022), reinstate a Phase 2C for AK (Q2-Q3 2022) and pursue pre-clinical on the newly patented molecules. An **extremely** low burning rate is expected, due to lean structure and accent on collaboration rather than high cap expenses for laboratory equipment and personal at this stage.

20M Euros was recently committed by an important Financial partner to be invested at Company demand and timing during the up to 3 years term of the investment contract following Registration of the shares for trading. An Audited (UK) valuation of the Company was a condition of the investor and was received..

Stage 2: Further investment will occur by Public Offering at market value to prepare a Phase 3 for AK and conduct a Phase 3 for CTCL as well as to explore back-up compounds & pathologies (Q1'22 – Q1'24). Co-development deal for a Phase 3 in AK is also under on-going discussions as source of financing.

Stage 3: A dual European and USA listing is in the program prior to commercialization of the products. Investors joining ViDAC Pharma's financing plan benefit from the outcomes of \$14M of research and development already invested by entrepreneurs and VCs before management buyout plus \$5M of non-dilutive grants.

Timeline

2019	2020-2022	2022 - 2023	2023 - 2024
VDA-1102 Phase 2 data Management Buyout	AK Phase 2b confirmation on selective population and reformulation Phase 2A for CTCL	Phase 3 in CTCL Co-development deal for AK/CTCL Inflection Value Point	Additional Pathology and molecules development. Preparing for commercialisation

Contact Information:

Max Herzberg PhD, direct +972544257381 or maxherzberg@gmail.com



Leading Team

Prof. Max Herzberg, Active Chairman, interim CEO

40 years of biotechnology industry experience, one of the founders of the Israel Biotech Industry, founder and board member of several successful biopharmaceutical companies. Inventor of the first API of Vidac.

Yochai Richter, Board Member

Successful entrepreneur. Chairman of Orbotech from its creation up to its \$4B exit.

Christian Policard PhD, Board Member

Former Executive VP of Sanofi and VP of Institut Pasteur, Head of Biotech Life Sciences Consulting firm.

Oren Becker PhD, Board Member

Former CEO of ViDAC Pharma, 20 years of experience in the biopharmaceutical industry and chain entrepreneur.

Merav Revach PhD, CTO 25 years of experience in the various stages of Drug development from R&D to post registration with the FDA.

Shuki Cohen CPA: CFO 30 years of experience in working with start-ups and established Companies in the Healthcare territory including budgeting and reporting to Grantors and Institutions and relations with VCs and Banks.

Prof. David Varon MD, CMO, Former Head of Hematology Department Hadassah Hospital-Jerusalem with a vast experience in practicing and researching General Medicine and performing Clinical Trials.

Intellectual Property: Strong patent position with several worldwide composition-of-matter and use patents (to be provided upon request). The Company comprehensive Portfolio covers both New Chemical Entities and the field of targeting HK2 in hyper glycolytic state of the Cancer cells (effect Warburg) as well as its immunological consequences particularly for Immunological and Cell directed treatments.

Contact Information:

Max Herzberg PhD, direct +972544257381 or maxherzberg@gmail.com